Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Preferred Shares (2016)

Arrowhead Pharmaceuticals' Preferred Shares history spans 5 years, with the latest figure at $16.0 for Q3 2016.

  • For Q3 2016, Preferred Shares changed 0.0% year-over-year to $16.0; the TTM value through Sep 2016 reached $16.0, changed 0.0%, while the annual FY2016 figure was $16.0, 0.0% changed from the prior year.
  • Preferred Shares reached $16.0 in Q3 2016 per ARWR's latest filing, roughly flat from $16.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $51.0 in Q4 2013 to a low of $10.0 in Q2 2013.
  • Average Preferred Shares over 4 years is $18.64, with a median of $16.0 recorded in 2015.
  • The largest YoY upside for Preferred Shares was 110.0% in 2014 against a maximum downside of 64.71% in 2014.
  • A 4-year view of Preferred Shares shows it stood at $51.0 in 2013, then tumbled by 64.71% to $18.0 in 2014, then fell by 11.11% to $16.0 in 2015, then changed by 0.0% to $16.0 in 2016.
  • Per Business Quant, the three most recent readings for ARWR's Preferred Shares are $16.0 (Q3 2016), $16.0 (Q2 2016), and $16.0 (Q1 2016).